6/11
02:04 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
6/5
07:13 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $31.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $31.00 price target on the stock.
6/3
02:01 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
6/3
10:11 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
6/3
07:39 am
arwr
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome [Yahoo! Finance]
6/3
07:30 am
arwr
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
High
Report
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
5/31
07:49 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences [Yahoo! Finance]
5/31
07:30 am
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
5/30
05:44 am
arwr
Stuttering Market to Register Stunning Growth at a CAGR of 13.4% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Stuttering Market to Register Stunning Growth at a CAGR of 13.4% by 2034 | DelveInsight [Yahoo! Finance]
5/29
05:35 am
arwr
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia [Yahoo! Finance]
5/29
05:30 am
arwr
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
Medium
Report
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
5/28
06:15 am
arwr
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia [Yahoo! Finance]
5/28
06:04 am
arwr
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Medium
Report
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
5/23
09:34 am
arwr
Merck's MilliporeSigma agrees to acquire Mirus Bio for $600m [Yahoo! Finance]
Low
Report
Merck's MilliporeSigma agrees to acquire Mirus Bio for $600m [Yahoo! Finance]
5/23
08:15 am
arwr
Gamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 Million [Yahoo! Finance]
Medium
Report
Gamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 Million [Yahoo! Finance]
5/22
01:40 pm
arwr
MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing [Yahoo! Finance]
Low
Report
MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing [Yahoo! Finance]
5/21
04:13 am
arwr
Alpha-1 Antitrypsin Deficiency Market and Epidemiology Forecast to 2032 [Yahoo! Finance]
Low
Report
Alpha-1 Antitrypsin Deficiency Market and Epidemiology Forecast to 2032 [Yahoo! Finance]
5/20
06:05 am
arwr
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma [Yahoo! Finance]
5/20
06:00 am
arwr
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
Low
Report
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
5/13
01:27 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target lowered by analysts at Morgan Stanley from $36.00 to $27.00. They now have an "equal weight" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its price target lowered by analysts at Morgan Stanley from $36.00 to $27.00. They now have an "equal weight" rating on the stock.
5/13
12:16 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
5/10
12:30 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript [Yahoo! Finance]
5/10
11:24 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
5/9
04:35 pm
arwr
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results [Yahoo! Finance]
5/9
04:01 pm
arwr
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
Medium
Report
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results